Fas death pathway in sarcomas correlates with epidermal growth factor transcription

David E. Joyner, Albert J. Aboulafia, Timothy A. Damron, R Randall

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Modulation of apoptosis may influence sarcoma pathogenesis and/or aggressiveness. The Fas death pathway, mediated by FasL or TGFβ, is one of two apoptotic pathways. Recent studies report that EGF can modulate TGFβ and/or FasL expression/activity; thus, EGF has the potential to influence activation of the Fas pathway. EGF is not always detectable in mesenchymal tumors; therefore, we hypothesized EGF would define which Fas ligand predominates. We assayed 57 surgically removed human sarcomas for 10 genes involved in the Fas pathway. Skeletal muscle biopsies from eight patients served as controls. Sample transcripts were detected by real-time RT-PCR. We attempted to identify relevant predictor variables. The 57 sarcomas were segregated into two categories defined by EGF mRNA content: (1) 23 tumors with EGF concentrations that approximated muscle EGF transcript levels (high-EGF tumors); and (2) 34 tumors that either lacked EGF mRNA, or whose mRNA levels were very low and frequently undetected by PCR (low-EGF tumors). TGFβ1 expression best predicted Fas transcript concentrations in the 34 low-EGF sarcomas, while FasL predicted Fas mRNA levels in the remaining 23 high-EGF sarcomas. The results suggest ligand activity in the Fas death pathway correlates with EGF transcription in sarcomas.

Original languageEnglish (US)
Pages (from-to)2092-2098
Number of pages7
JournalClinical Orthopaedics and Related Research
Volume466
Issue number9
DOIs
StatePublished - Sep 1 2008
Externally publishedYes

Fingerprint

Epidermal Growth Factor
Sarcoma
Messenger RNA
Neoplasms
Fas Ligand Protein
Real-Time Polymerase Chain Reaction
Skeletal Muscle
Apoptosis
Ligands
Biopsy

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Fas death pathway in sarcomas correlates with epidermal growth factor transcription. / Joyner, David E.; Aboulafia, Albert J.; Damron, Timothy A.; Randall, R.

In: Clinical Orthopaedics and Related Research, Vol. 466, No. 9, 01.09.2008, p. 2092-2098.

Research output: Contribution to journalArticle

Joyner, David E. ; Aboulafia, Albert J. ; Damron, Timothy A. ; Randall, R. / Fas death pathway in sarcomas correlates with epidermal growth factor transcription. In: Clinical Orthopaedics and Related Research. 2008 ; Vol. 466, No. 9. pp. 2092-2098.
@article{30bbf1089be64f38bb369e5fdeab7cd9,
title = "Fas death pathway in sarcomas correlates with epidermal growth factor transcription",
abstract = "Modulation of apoptosis may influence sarcoma pathogenesis and/or aggressiveness. The Fas death pathway, mediated by FasL or TGFβ, is one of two apoptotic pathways. Recent studies report that EGF can modulate TGFβ and/or FasL expression/activity; thus, EGF has the potential to influence activation of the Fas pathway. EGF is not always detectable in mesenchymal tumors; therefore, we hypothesized EGF would define which Fas ligand predominates. We assayed 57 surgically removed human sarcomas for 10 genes involved in the Fas pathway. Skeletal muscle biopsies from eight patients served as controls. Sample transcripts were detected by real-time RT-PCR. We attempted to identify relevant predictor variables. The 57 sarcomas were segregated into two categories defined by EGF mRNA content: (1) 23 tumors with EGF concentrations that approximated muscle EGF transcript levels (high-EGF tumors); and (2) 34 tumors that either lacked EGF mRNA, or whose mRNA levels were very low and frequently undetected by PCR (low-EGF tumors). TGFβ1 expression best predicted Fas transcript concentrations in the 34 low-EGF sarcomas, while FasL predicted Fas mRNA levels in the remaining 23 high-EGF sarcomas. The results suggest ligand activity in the Fas death pathway correlates with EGF transcription in sarcomas.",
author = "Joyner, {David E.} and Aboulafia, {Albert J.} and Damron, {Timothy A.} and R Randall",
year = "2008",
month = "9",
day = "1",
doi = "10.1007/s11999-008-0313-5",
language = "English (US)",
volume = "466",
pages = "2092--2098",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Fas death pathway in sarcomas correlates with epidermal growth factor transcription

AU - Joyner, David E.

AU - Aboulafia, Albert J.

AU - Damron, Timothy A.

AU - Randall, R

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Modulation of apoptosis may influence sarcoma pathogenesis and/or aggressiveness. The Fas death pathway, mediated by FasL or TGFβ, is one of two apoptotic pathways. Recent studies report that EGF can modulate TGFβ and/or FasL expression/activity; thus, EGF has the potential to influence activation of the Fas pathway. EGF is not always detectable in mesenchymal tumors; therefore, we hypothesized EGF would define which Fas ligand predominates. We assayed 57 surgically removed human sarcomas for 10 genes involved in the Fas pathway. Skeletal muscle biopsies from eight patients served as controls. Sample transcripts were detected by real-time RT-PCR. We attempted to identify relevant predictor variables. The 57 sarcomas were segregated into two categories defined by EGF mRNA content: (1) 23 tumors with EGF concentrations that approximated muscle EGF transcript levels (high-EGF tumors); and (2) 34 tumors that either lacked EGF mRNA, or whose mRNA levels were very low and frequently undetected by PCR (low-EGF tumors). TGFβ1 expression best predicted Fas transcript concentrations in the 34 low-EGF sarcomas, while FasL predicted Fas mRNA levels in the remaining 23 high-EGF sarcomas. The results suggest ligand activity in the Fas death pathway correlates with EGF transcription in sarcomas.

AB - Modulation of apoptosis may influence sarcoma pathogenesis and/or aggressiveness. The Fas death pathway, mediated by FasL or TGFβ, is one of two apoptotic pathways. Recent studies report that EGF can modulate TGFβ and/or FasL expression/activity; thus, EGF has the potential to influence activation of the Fas pathway. EGF is not always detectable in mesenchymal tumors; therefore, we hypothesized EGF would define which Fas ligand predominates. We assayed 57 surgically removed human sarcomas for 10 genes involved in the Fas pathway. Skeletal muscle biopsies from eight patients served as controls. Sample transcripts were detected by real-time RT-PCR. We attempted to identify relevant predictor variables. The 57 sarcomas were segregated into two categories defined by EGF mRNA content: (1) 23 tumors with EGF concentrations that approximated muscle EGF transcript levels (high-EGF tumors); and (2) 34 tumors that either lacked EGF mRNA, or whose mRNA levels were very low and frequently undetected by PCR (low-EGF tumors). TGFβ1 expression best predicted Fas transcript concentrations in the 34 low-EGF sarcomas, while FasL predicted Fas mRNA levels in the remaining 23 high-EGF sarcomas. The results suggest ligand activity in the Fas death pathway correlates with EGF transcription in sarcomas.

UR - http://www.scopus.com/inward/record.url?scp=50649097016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649097016&partnerID=8YFLogxK

U2 - 10.1007/s11999-008-0313-5

DO - 10.1007/s11999-008-0313-5

M3 - Article

C2 - 18506556

AN - SCOPUS:50649097016

VL - 466

SP - 2092

EP - 2098

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 9

ER -